Skip to content
TrialScanner

NCT02174419

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Phase 2/Phase 3CompletedTRVILead

Registry record

Lead sponsor
Trevi Therapeutics
Conditions
Prurigo Nodularis; Nodularis Prurigo; Prurigo; Pruritus
Primary completion
Aug 2016Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02174419 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02174419: Study of Nalbuphine HCl ER... | TrialScanner